English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
VOLUNTARY ANNOUNCEMENT - THE INTERIM ANALYSIS OF A PIVOTAL PHASE II/III CLINICAL TRIAL OF KN026 HAS MET THE PRIMARY ENDPOINT OF PFS
2025-04-30
VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES OF JSKN021 AND JSKN022 FOR PRESENTATION AT 2025 AACR ANNUAL MEETING
2025-04-30
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2025-04-28
(1) GRANT OF SHARE OPTIONS UNDER THE POST-IPO SHARE OPTION SCHEME; AND (2) GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME
2025-04-23
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
2025-04-03
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
2025-03-25
JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE NMPA
2025-03-18
DATE OF BOARD MEETING
2025-03-06
POSITIVE PROFIT ALERT
2025-03-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
2025-03-04
1
2
3
4
PREV
1/27
NEXT